Burning Rock Schedules Fourth Quarter and Full Year 2022 Earnings Release on March 28, 2023
- GUANGZHOU, China, March 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the fourth quarter and full year 2022 before the U.S. market opens on March 28, 2023. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the fourth quarter and full year 2022.
- 03/07/2023
|
Burning Rock Biotech Limited Sponsored ADR (BNR) Upgraded to Buy: What Does It Mean for the Stock?
- Burning Rock Biotech Limited Sponsored ADR (BNR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 11/21/2022
|
Burning Rock Biotech (BNR) Q3 2022 Earnings Call Transcript
- Burning Rock Biotech Limited (NASDAQ:BNR ) Q3 2022 Earnings Conference Call November 16, 2022 8:30 AM ET Company Participants Yusheng Han - Chairman and CEO Dr. Shaokun Chuai - COO Leo Li - CFO Conference Call Participants Alexis Yan - Morgan Stanley Max Masucci - Cowen & Company Operator Good day and thank you for standing by. Welcome to the Burning Rock 2022 Third Quarter Earnings Conference Call.
- 11/16/2022
|
Burning Rock Provides Third Quarter 2022 Business Updates and Schedules Earnings Release on November 16, 2022
- GUANGZHOU, China, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2022 before the U.S. market opens on November 16, 2022. Following the release, company management will host a conference call at 8:30 a.m. ET (9:30 p.m. Hong Kong time) on the same day to discuss its financial results for the third quarter of 2022.
- 10/25/2022
|
Best Penny Stocks To Buy? 4 That Redditors Are Watching Now
- Penny stocks to buy according to Reddit sentiment. The post Best Penny Stocks To Buy?
- 08/31/2022
|
Why Shares of Alibaba, JD.com, and Burning Rock Biotech Are Rising Today
- Chinese stocks continue to benefit from a preliminary agreement between the U.S. and China on a long-standing auditing dispute.
- 08/31/2022
|
Burning Rock Biotech (BNR) Q2 2022 Earnings Call Transcript
- Burning Rock Biotech Limited (NASDAQ:BNR ) Q2 2022 Earnings Conference Call August 31, 2022 8:30 AM ET Company Participants Yusheng Han - Chief Executive Officer Shannon Chuai - Chief Operating Officer Leo Li - Chief Financial Officer Conference Call Participants Stephanie - Cowen Operator Good day and thank you for standing by. Welcome to the Burning Rock 2022 Q2 earnings conference call and webcast.
- 08/31/2022
|
Burning Rock Biotech Limited Sponsored ADR (BNR) Reports Q2 Loss, Tops Revenue Estimates
- Burning Rock Biotech Limited Sponsored ADR (BNR) delivered earnings and revenue surprises of -2.78% and 0.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/31/2022
|
Burning Rock Provides Second Quarter 2022 Business Updates and Schedules Earnings Release on August 31, 2022
- GUANGZHOU, China, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the second quarter of 2022 before the U.S. market opens on August 31, 2022. Following the release, company management will host a conference call at 8:30 a.m. ET (8:30 p.m. Hong Kong time) on the same day to discuss its financial results for the second quarter of 2022.
- 08/04/2022
|
Cathie Wood Is Selling Gene Editing Stocks. Here's Why.
- Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?
- 06/02/2022
|
Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q1 2022 Results - Earnings Call Transcript
- Burning Rock Biotech Limited (NASDAQ:BNR ) Q1 2022 Earnings Conference Call May 31, 2022 8:30 AM ET Company Participants Yusheng Han - Founder, Chairman & CEO Leo Li - CFO Shannon Chuai - COO Conference Call Participants Max Masucci - Cowen & Company Alexis Yan - Morgan Stanley Operator Good day, ladies and gentlemen, thank you for standing by, and welcome to Burning Rock 2022 First Quarter Earnings Conference Call. This presentation contains forward-looking statements.
- 05/31/2022
|
Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
- GUANGZHOU, China, May 16, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2022 before the U.S. market opens on May 31, 2022. Following the release, company management will host a conference call at 8:30 a.m. ET (8:30 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2022.
- 05/16/2022
|
Tesla Bull Cathie Wood Bought $1M Shares In This Biotech Stock Today
- Tesla Inc (NASDAQ: TSLA) bull Cathie Wood led Ark Investment Management on Thursday further raised its exposure in China-based biotech company Burning Rock Biotech Ltd (NASDAQ: BNR). The investment firm bought 112,150 shares — estimated to be worth $1.08 million — in the biotech company.
- 03/24/2022
|
Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q4 2021 Results - Earnings Call Transcript
- Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q4 2021 Results - Earnings Call Transcript
- 03/22/2022
|
Burning Rock Schedules Fourth Quarter and Full Year 2021 Earnings Release on March 22, 2022
- GUANGZHOU, China, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the fourth quarter and full year 2021 before the U.S. market opens on March 22, 2022. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the fourth quarter and full year 2021.
- 02/21/2022
|
Following Rough Year, Is Burning Rock Set To Turn The Corner?
- Key Takeaways: Burning Rock expects fourth-quarter revenue to grow just 6% year-on-year due to latest Covid-related travel restrictions in China
- 11/18/2021
|
ARK Genomic Revolution fund starts position in Burning Rock Biotech
- The ARK Genomic Revolution ETF ARKG, +2.01% started a position in Burning Rock Biotech BNR, +10.69% , a Chinese cancer sequencing technology company that jumped 11% after reporting third-quarter results. The loss-making biotech saw its revenue edge up 2% in the third quarter and is planning two products for early-stage cancer patients next year.
- 11/17/2021
|
Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q3 2021 Results - Earnings Call Transcript
- Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q3 2021 Results - Earnings Call Transcript
- 11/16/2021
|
Recap: Burning Rock Biotech Q3 Earnings
- Burning Rock Biotech (NASDAQ:BNR) reported its Q3 earnings results on Tuesday, November 16, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
- 11/16/2021
|
Burning Rock Schedules Third Quarter of 2021 Earnings Release on November 16, 2021
- GUANGZHOU, China, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company foused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2021 before the U.S. market opens on November 16, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET (9:00 p.m. Hong Kong time) on the same day to discuss its financial results for the third quarter of 2021.
- 11/03/2021
|
Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q2 2021 Results - Earnings Call Transcript
- Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q2 2021 Results - Earnings Call Transcript
- 08/31/2021
|
Burning Rock Reports Second Quarter 2021 Financial Results
- GUANGZHOU, China, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2021.
- 08/31/2021
|
Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion Diagnostics Development
- GUANGZHOU, China, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field of synthetic lethality. The two companies will jointly develop CDx for a targeted oncology drug, Senaparib (IMP4297), a PARP inhibitor, for the treatment of prostate cancer globally, including CDx submissions to both the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration of China (NMPA). The global program will be supported by Burning Rock's Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited labs in Guangzhou, China and California, U.S. Furthermore, the two companies will deepen collaborations in exploring and discovering new biomarkers for a pipeline of targeted drugs.
- 08/03/2021
|
Burning Rock Schedules Second Quarter of 2021 Earnings Release on August 31, 2021
- GUANGZHOU, China, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the second quarter of 2021 before the U.S. market opens on August 31, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the second quarter of 2021.
- 08/02/2021
|
New Strong Sell Stocks for June 24th
- RAD, WTRH, BNR, NMR, and VNCE have been added to the Zacks Rank #5 (Strong Sell) List on June 24, 2021
- 06/24/2021
|
New Strong Sell Stocks for June 11th
- BLIN, BNR, MOV, BAP and SBRA have been added to the Zacks Rank #5 (Strong Sell) List on June 11, 2021.
- 06/11/2021
|
New Strong Sell Stocks for June 3rd
- ADSK, BNR, NET, ELMD, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on June 3, 2021
- 06/03/2021
|
Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q1 2021 Results - Earnings Call Transcript
- Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q1 2021 Results - Earnings Call Transcript
- 05/25/2021
|
Burning Rock Reports First Quarter 2021 Financial Results
- GUANGZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2021.
- 05/25/2021
|
Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal
- LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreement.
- 05/23/2021
|
Pharmaron, I-Mab And Burning Rock Get Investor Validation From MSCI
- MSCI's addition of Pharmaron, I-Mab and Burning Rock to its China All Shares Index highlights their strong growth potential. Inclusion typically represents validation for a company's products and outlook.
- 05/21/2021
|
Burning Rock Announces the Launch of China's First Prospective Pan-Cancer Multi-omics Early Detection Study
- BEIJING, May 19, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced the launch of the PRESCIENT (Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT) study, the first blood-based, pan-cancer early-detection study in China using a multi-omics approach. The study is going to be led by Professor Jie He, Fellow of the Chinese Academy of Sciences and head of the China National Cancer Center, and Professor Jie Wang. Both are residing physicians at the National Cancer Center and the Cancer Hospital of the Chinese Academy of Medical Sciences.
- 05/19/2021
|
Burning Rock to be Added to MSCI China Index
- GUANGZHOU, China, May 12, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will be included in the MSCI China Index, effective after the U.S. market close on May 27, 2021. Burning Rock is the only NGS-based precision oncology company from China that has been selected in the current MSCI semi-annual index review.
- 05/12/2021
|
Burning Rock Schedules First Quarter of 2021 Earnings Release on May 25, 2021
- GUANGZHOU, China, April 28, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2021 before the U.S. market opens on May 25, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2021.
- 04/28/2021
|
Burning Rock's Liquid Biopsy Assay Achieved Strong Performance in the FDA-led SEQC2 Study, with Results Published on Nature Biotechnology
- GUANGZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that its liquid biopsy assay has achieved strong performance in the FDA-led Sequencing Quality Control Phase 2 (SEQC2) study, the results of which have been published on Nature Biotechnology.
- 04/13/2021
|
Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q4 2020 Results - Earnings Call Transcript
- Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q4 2020 Results - Earnings Call Transcript
- 03/11/2021
|
Burning Rock Reports Fourth Quarter and Full Year 2020 Financial Results
- GUANGZHOU, China, March 10, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and year ended December 31, 2020.
- 03/10/2021
|
Burning Rock Announces Preliminary Fourth Quarter and Full Year 2020 Results and Schedules Earnings Release on March 11, 2021
- GUANGZHOU, China, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited fourth quarter and full year 2020 financial results before the U.S. market opens on March 11, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET on (9:00 p.m. Hong Kong time) the same day to discuss its financial results for the fourth quarter and full year 2020.
- 02/08/2021
|
Burning Rock (BNR) in Focus: Stock Moves 5.4% Higher
- Burning Rock (BNR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- 01/22/2021
|
Burning Rock Biotech Expands Test Portfolio In Bid For Growth
- Burning Rock Biotech went public in the U.S. in June 2020. The firm provides a range of early detection and therapy selection testing services in China.
- 12/30/2020
|
OCX Stock: Why Shares of Biotech OncoCyte Are Skyrocketing Today
- Shares of OCX stock are blasting off on Tuesday morning after a major company agreement with an important China-based biotech firm. The post OCX Stock: Why Shares of Biotech OncoCyte Are Skyrocketing Today appeared first on InvestorPlace.
- 12/15/2020
|
The Daily Biotech Pulse: CureVac Close To Coronavirus Vaccine Deal With EU, Entera Bio's Positive Readout, Patent Protection For Co-Diagnostics
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
- 08/20/2020
|
The Daily Biotech Pulse: Poseida's Phase 1 Study Placed On Clinical Hold, Orphan Drug Designation For Krystal Biotech, Tiziana's Patent Award
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Catalent Inc (NYSE: CTLT)
CureVac N.V. (NASDAQ: CVAC) (follow-on buying after a 250% advance on its debut Friday...
- 08/18/2020
|
Burning Rock Reports Second Quarter 2020 Financial Results
- GUANGZHOU, China, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2020.Second Quarter 2020 Highlights * Revenues of RMB107.0 million (US$15.1 million) for the three months ended June 30, 2020, representing a 26.1% increase over the corresponding period in 2019. * Key publications: * BENEFIT biomarker study (with AstraZeneca) published in Journal of Thoracic Oncology1 * Blood-based MSI validation published in Journal of Molecular Diagnostics2 * NSCLC liquid-biopsy real-world validation (COMPASS) published in Translational Lung Cancer Research3 * Clinical validation and genetic landscape studies on multiple cancer types including breast cancer,4 lymphoma,5 etc. * Entered into collaboration with Illumina on developing IVD kit solutions on the NextSeq 550Dx system, building on the two companies’ successful collaboration back in 2015 on the MiSeq Dx system that led to the first NMPA (National Medical Products Administration) approved NGS panel for the China market. * Entered into collaboration with CStone Pharmaceuticals (2616.HK) on CDx development for pralsetinib. * Progressing on the training and validation of the Company’s 6-cancer test, which builds on the Company’s 3-cancer test demonstrated in January 2020, with improved assay and bioinformatics. * Launched the PREDICT (Pan-CanceR Early DetectIon ProjeCT) study, a prospective, multi-center study that is expected to enroll 14,000 patients in China, to develop and validate the Company’s pan-cancer early detection test. * Completed initial public offering and concurrent private placement, with an aggregate offering size of US$281.2 million (giving effect to the full exercise of the over-allotment option).“We appreciate existing and new shareholders’ valuable support towards our IPO in June, the largest IPO by a molecular diagnostics company from China, as we look to leveraging the proceeds raised to catalyze our growth trajectory,” said Yusheng Han, chairman and chief executive officer of Burning Rock. “Amid sporadic COVID incidents in China during the second quarter, we returned to positive year-over-year revenue growth. We continued our efforts to bring NGS testing capability in-house for hospitals through our decentralized, kit based, in-hospital channel; we also advanced our market leadership position in the central-laboratory channel where samples are sent out to third-party laboratories for testing. For early cancer detection, after four years of internal R&D, we launched the 14,000 patient PREDICT study during the second quarter, the first early detection study in multiple cancer types in China, to further develop and validate our blood-based test.”Second Quarter 2020 Financial ResultsRevenues were RMB107.0 million (US$15.1 million) for the three months ended June 30, 2020, representing a 26.1% increase from RMB84.8 million for the same period in 2019. * Revenue generated from central laboratory business was RMB74.6 million (US$10.6 million) for the three months ended June 30, 2020, representing a 17.7% increase from RMB63.4 million for the same period in 2019, primarily attributable to resumed volume growth of the Company’s central laboratory business. This reversed the 37% year-over-year decreasing trend during the first quarter. Number of patients tested in the central laboratory channel increased by 19.9% to 7,252 for the three months ended June 30, 2020 from 6,047 for the same period in 2019. * Revenue generated from in-hospital business was RMB27.6 million (US$3.9 million) for the three months ended June 30, 2020, representing a 69.0% increase from RMB16.3 million for the same period in 2019, driven by resumed kit revenue growth of existing contracted hospitals and ramp-up of newly contracted hospitals. This reversed the 36% year-over-year decreasing trend during the first quarter. Number of contracted partner hospitals in the in-hospital channel increased to 24 as of June 30, 2020 from 21 as of March 31, 2020 and 19 as of December 31, 2019. * Revenue generated from pharma research and development services was RMB4.8 million (US$0.6 million) for the three months ended June 30, 2020, representing a 6.2% decrease from RMB5.1 million for the same period in 2019.Cost of revenues was RMB28.6 million (US$4.0 million) for the three months ended June 30, 2020, representing a 25.6% increase from RMB22.8 million for the same period in 2019, which was in line with the Company’s continued business growth.Gross profit was RMB78.4 million (US$11.1 million) for the three months ended June 30, 2020, representing a 26.3% increase from RMB62.0 million for the same period in 2019. Gross margin was 73.3% for the three months ended June 30, 2020, compared to 73.2% for the same period in 2019.Operating expenses were RMB151.4 million (US$21.4 million) for the three months ended June 30, 2020, representing a 67.3% increase from RMB90.5 million for the same period in 2019. * Research and development expenses were RMB71.2 million (US$10.1 million) for the three months ended June 30, 2020, representing an 103.4% increase from RMB35.0 million for the same period in 2019, primarily due to an increase in share-based compensation expenses for options granted to research and development personnel. * Selling and marketing expenses were RMB38.0 million (US$5.4 million) for the three months ended June 30, 2020, representing an 8.8% increase from RMB34.9 million for the same period in 2019. * General and administrative expenses were RMB42.2 million (US$5.9 million) for the three months ended June 30, 2020, representing an 105.1% increase from RMB20.6 million for the same period in 2019, primarily due to (i) an increase in staff cost, which was in line with the continued growth of the Company’s business, and (ii) expenses related to the Company’s initial public offering.Net loss was RMB71.1 million (US$10.1 million), compared to RMB26.0 million for the same period in 2019.Cash, cash equivalents and restricted cash were RMB2.6 billion (US$363.2 million) as of June 30, 2020.2020 Financial GuidanceAssuming no significant resurgence of the COVID pandemic in China, Burning Rock expects its full year 2020 revenues to be approximately RMB420 million (US$59.4 million), implying a 28% year-over-year growth in the second half of 2020 compared with the same period in 2019.Conference Call InformationBurning Rock will host a conference call to discuss the second quarter 2020 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on August 11, 2020.Details of the conference call are as follows:International:+65 67135090 U.S.:18665194004 U.K.:08082346646 Hong Kong:+852 30186771 China Mobile:4006208038 China Landline:8008190121 Conference ID:4765946 A replay of the conference call will be available for two weeks (dial-in number: +61 2 8199 0299; same conference ID as shown above). About Burning RockBurning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.For more information about Burning Rock, please visit: www.brbiotech.com.Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law._____________________________1 Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal circulating tumor DNA Monitoring in Advanced EGFR-mutant Lung Adenocarcinoma under Gefitinib Treatment. Accepted, Journal of Thoracic Oncology.2 Detection of Microsatellite Instability from Circulating Tumor DNA by Targeted Deep Sequencing. Journal of Molecular Diagnostic.
- 08/11/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Burning Rock Schedules Second Quarter of 2020 Earnings Release on August 11, 2020
- GUANGZHOU, China, July 20, 2020 -- Burning Rock Biotech Limited (NASDAQ: BNR) today announced that it plans to release its unaudited financial results for the second quarter of.
- 07/21/2020
|
Stocks To Watch: Postmates, Walgreens And Cannabis Plays
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 07/04/2020
|
Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China
- On June 29, 2020, Burning Rock Biotech Limited (BNR) announced a strategic partnership with CStone Pharmaceuticals (2616.HK) to co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s partner Blueprint Medicines, in China for the detection of RET alterations in cancer patients. CStone’s partner Blueprint Medicines released promising global data for pralsetinib this June at ASCO 2020.
- 06/29/2020
|
Burning Rock Announces Full Exercise of Over-Allotment Option in Initial Public Offering
- GUANGZHOU, China, June 22, 2020 -- Burning Rock Biotech Limited (“Burning Rock” or the “Company”) (NASDAQ: BNR), a company focused on the application of next generation.
- 06/22/2020
|
U.S. IPO Weekly Recap: Royalty Pharma Takes The Crown In 5 IPO Week
- Five IPOs and one SPAC went public this past week led by Royalty Pharma. Healthcare continued to dominate, with all five IPOs coming from the sector. Seven IPOs
- 06/20/2020
|
